Jianmin Pharmaceutical Group Co (SHSE:600976) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600976 Jianmin Pharmaceutical Group Co Ltd SHSE:600976
65 GF Score
Price ¥27.21
GF Value ¥39.48
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Jianmin Pharmaceutical Group Co Short-term investments?

Short-term investments only applies to insurance companies.

SHSE:600976
65GF Score
Jianmin Pharmaceutical Group Co Ltd SHSE:600976
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jianmin Pharmaceutical Group Co (SHSE:600976) Overvalued in 2026?

Based on GuruFocus' analysis, Jianmin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥27.21 is trading 31.1% below its estimated GF Value™ of ¥39.48. GuruFocus considers Jianmin Pharmaceutical Group Co to be Significantly Undervalued.

Key valuation signals for SHSE:600976:

  • Short-term investments:
  • GF Value™: ¥39.48 vs. price of ¥27.21 (31.1% below fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600976 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jianmin Pharmaceutical Group Co Business Description

Address No. 484, Yingwu Avenue, Hanyang District, Hubei Province, Wuhan, CHN, 430052
Jianmin Pharmaceutical Group Co Ltd is a Chinese pharmaceutical company engaged in the research, development, manufacture, and distribution of medicines, with a strategic focus on pediatric medicine, gynecological medicine, and specialty traditional Chinese medicine. The company markets products under brands including Jianmin and Longmu, covering prescription drugs, over-the-counter medicines, and traditional Chinese medicine formulations. Its portfolio spans pediatric remedies, women's health treatments, and other therapeutic categories sold through hospitals, pharmacies, and distribution partners across China. Revenue is generated primarily through the sale of its pharmaceutical products, supported by manufacturing operations and a nationwide distribution network. The company operates mainly in the domestic Chinese market, where demand for pediatric and gynecological treatments is substantial, and it continues to develop and commercialize new drug products within its core therapeutic areas.
65GF Score

Get the complete analysis for SHSE:600976

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.21
Price
¥39.48
GF Value